ADAPT 2010: Accelerating Development & Advancing Personalized Therapy
（ADAPT 2010：个别化治疗的开发促进与进步）
2010年9月13-16日 美国阿灵顿

会前研讨会

Short Course: Fit-For-Purpose Biomarker Assay Development and Validation
Executive Think Tank: Strategies for Drug-Diagnostic Co-Development

活动重点：

人脉：来自20几个以上国家、超过275个组织、500多名代表者参加。
学习：超过100场发表，50多张海报与30个展示摊位。
存取数据： 以个别化医疗、癌、生物标记、诊断药、治疗效验等做为主题的5个历程。

为使新药开发迅速与针对成本削减的压力，须有一一因应患者的治疗法。且为提供开发药剂与诊断的桥梁、早期诊断、及更个别化的诊断，要活用新的技术。为更迅速且做出效率高的意思决定，重新开发药剂等的重要性深受瞩目。ADAPT 2010：Accelerating Development & Advancing Personalized Therapy Congress详细验证个别化医疗、癌、生物标记、诊断药、治疗效验，且设计要成为复合领域的桥梁。

去年开始的ADAPT会议，举办了包含新主题、长时间的各种活动，有超过20个国家之275家以上公司的机关、450多人参加。预计今年加上诊断药、个别化医疗、癌等新主题，将更扩大规模举办，邀请海外大·中规模的制药公司和生物工艺学企业、诊断药厂商、有名大学、临床研究机关、政府、国立试验所、CRO、新兴企业、工具服务提供商等，使其成为向专家学习研究的最新动向，进行意见交换与促进产官合作，评估新兴技术的理想聚会。

2010年的新内容:

• 网罗个别化医疗模式、开发药剂与诊断的桥梁等广泛的主题
• 加上循环肿瘤细胞，有关癌研究的主题追加癌干细胞、癌染色体组的展开、癌生物标记等
• 新的Diagnostic Development历程网罗分子诊断的最新动向
• 在新的preconference新企业介绍展中出刊以新兴企业与新技术等为内容的特集
• 继2009年之后，举办与生物标记开发及设计适合治疗效验有关的长时间会议

 

Preliminary Speaker List:  

• John L. Allinson, FIBMS, Vice President, Biomarker Laboratory Services, ICON Development Solutions
• Zoran Antonijevic, Senior Director, Center for Statistics in Drug Development, Quintiles
• Haifeng Bao, Ph.D., Research & Development, Translational Sciences, MedImmune
• Emily Boja, Ph.D., Program Manager, Clinical Proteomic Technologies for Cancer, Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health
• Brian Buxton, M.B.A., Principal, Easton Associates, LLC
• Walter P. Carney, Ph.D., Head, Oncogene Science, Siemens Healthcare Diagnostics, Inc.
• Jeffrey J. Chalmers, Ph.D., Professor, Department of Chemical and Biomolecular Engineering, The Ohio State University
• Mark Chance, Ph.D., Professor and Director, Center for Mass Spectrometry & Proteomics, Case Western Reserve University
• Jason Clark, Ph.D., Associate Director, BARDS, Merck Research Labs
• Brent Cochran, Ph.D., Principle Investigator, Physiology, Tufts University School of Medicine
• Viswanath Devanarayan, Ph.D., Director, Statistics, Biomarker Research, Abbott Laboratories
• Krassen Dimitrov, Ph.D., Group Leader, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Australia
• Jennifer Dudinak, Ph.D., Global Head, Inflammation, Regulatory Affairs, Roche
• Martin Fleisher, Ph.D., Chair, Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center
• Markus H. Frank, M.D., Assistant Professor, Department of Pediatrics, Harvard Medical School; Assistant Professor, Pediatrics, Children's Hospital Boston; Associate Physician, Medicine, Brigham and Women's Hospital
• Eugene Frenkel, M.D., Professor, Medicine and Radiology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical School
• Jian-Xin Gao, M.D., Ph.D., Assistant Professor, Department of Pathology, Ohio State University Medical Center
• Jeffrey N. Gibbs, J.D., Director, Hyman, Phelps and McNamara, P.C.
• Franz Hessel, M.D., M.P.H., Director, International Health Economics Outcomes Research, Abbott Diagnostics
• Elaine K. Jeter, M.D., Medical Director, Medical Affairs, Palmetto GBA
• Joshua LaBaer, M.D., Ph.D., Director, Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University
• Jae K. Lee, Ph.D., Director and Associate Professor, Biostatistics and Epidemiology, Department of Public Health Sciences, University of Virginia School of Medicine  
• Kenneth Liu, Ph.D., Senior Biometrician, Merck & Co.
• Minetta C. Liu, M.D., Associate Professor, Medicine and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital
• Nita Maihle, Ph.D., Professor, Ob/Gyn & Reproductive Sciences and Pathology, Yale University School of Medicine
• Ramkumar Mandalam, President and Chief Executive Officer, Cellerant Therapeutics
• David H. Manner, Ph.D., Group Leader, Exploratory and Program Medical Statistics, Eli Lilly
• Stuart S. Martin, Ph.D., Associate Professor, Physiology, University of Maryland School of Medicine
• Robert McCormack, Ph.D., Vice President, Scientific and Medical Affairs, Veridex, LLC
• Gerry J. McDougall, Partner, Personalized Medicine and Health Sciences Practices, PricewaterhouseCoopers LLP
• Gary Means, Ph.D., Principal Scientist, Molecular Sciences Group, Amgen, Inc.
• Gilbert S. Omenn, Ph.D., Director, Center for Computational Medicine and Bioinformatics, University of Michigan School of Medicine
• Emanuel Petricoin, Ph.D., Co-Director, Center for Applied Proteomics and Molecular Medicine; Professor, Life Sciences, George Mason University
• David R. Shalinsky, Ph.D., Associate Director, Translational Medicine, Pfizer Global Research and Development
• Zhenming Shun, Ph.D., Director, U.S. Head, Oncology, Biostatistics and Programming, Sanofi-Aventis 
• Yu Shyr, Ph.D., Ingram Professor of Cancer Research; Chief and Director, Cancer Biostatistics Center, Vanderbilt University School of Medicine
• Daniel S. Spellman, Ph.D., Senior Research Biochemist, Proteomics, Merck Research Laboratories
• Zoltan Szallasi, M.D., Senior Scientist, Informatics Program, Children's Hospital Boston, Harvard Medical School
• Kay S. Tatsuoka, Ph.D., Manager, Discovery Biometrics/Quantitative Sciences, GlaxoSmithKline
• Paul Tempst, Ph.D., Director, Protein Center; Member and Professor, Molecular Biology Program, Memorial Sloan-Kettering Cancer Center
• Pantelis Vlachos, Ph.D., Principal Biostatistician, Merck Serono International S.A.
• J. Kyle Wathen, Ph.D., Research Statistician, University of Texas, M.D. Anderson Cancer Center
• Glen Weiss, M.D., Co-Head, Lung Cancer Unit, Translational Genomics Research Institute (TGen); Director, Thoracic Oncology, TGen Clinical Research Services at Scottsdale Healthcare
• Anne Wiles, Advanced Analytics Strategist, Health and Life Sciences, SAS Institute, Inc.
• Stephen Wong, Ph.D., Director, Center for Bioengineering and Informatics, The Methodist Hospital Research Institute
• Vladimir Zharov, Ph.D., Professor and Director, Philips Classic Laser & Nanomedicine Laboratories; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences

For more information, please contact us.